Harmony Biosciences to begin human trials of narcolepsy drug in 2025

Harmony Biosciences (HRMY) plans to initiate first-in-human trials in the second half of 2025 for BP1.15205, an orexin 2 receptor agonist targeting narcolepsy, following positive preclinical data demonstrating wake-promoting and cataplexy-suppressing effects; this development follows a strong Q1 2025 performance with revenues of $184.7 million, a 20% year-over-year increase driven by Wakix, and analysts from Oppenheimer and Mizuho issuing Outperform ratings. The company also settled patent litigation with Lupin, allowing a generic Wakix version no earlier than 2030.

Analysis

Harmony Biosciences (NASDAQ:HRMY) is demonstrating robust financial health and promising pipeline progression, positioning it favorably within the biotech sector. The company reported substantial revenue of $745 million with a market capitalization of $2.06 billion, underpinned by impressive gross profit margins of 78.34% and a strong trailing twelve-month revenue growth of 20.62%. This financial strength is further highlighted by its Q1 2025 results, where revenues reached $184.7 million, a 20% year-over-year increase surpassing analyst estimates, driven by its flagship narcolepsy treatment, Wakix. Earnings per share also significantly exceeded expectations at $1.03 against a forecast of $0.61. InvestingPro analysis suggests the company is undervalued and assigns it a "GREAT" financial health score. Key to its future growth is the experimental orexin 2 receptor (OX2R) agonist, BP1.15205, targeting narcolepsy. Preclinical data for BP1.15205 are encouraging, showing significant wake-promoting and cataplexy-suppressing effects in animal models, high potency (EC50 of 0.015 nM), over 600-fold selectivity for OX2R, and no adverse events in three-month toxicity studies at doses up to 300 mg/kg/day. First-in-human trials are slated for the second half of 2025, with topline data anticipated in 2026. Analyst sentiment is positive, with Oppenheimer initiating coverage with an Outperform rating and Mizuho Securities raising its price target to $48 while maintaining an Outperform rating. Furthermore, Harmony has solidified its market position by settling patent litigation with Lupin Limited, ensuring no generic Wakix competition until at least 2030, and having the U.S. Patent Office uphold its polymorph patent for pitolisant hydrochloride.

Key Decisions for Investors

• Given Harmony Biosciences' strong financial performance, positive preclinical results for BP1.15205, favorable analyst ratings, and InvestingPro's undervaluation assessment, investors could view the company as a potentially attractive investment.
• Investors should closely monitor the progress of BP1.15205, particularly the initiation of first-in-human trials in H2 2025 and the subsequent release of topline data in 2026, as these are significant de-risking events and potential catalysts for the stock.
• The secured patent exclusivity for Wakix until at least 2030 provides a degree of revenue visibility and should be factored into long-term growth assessments, alongside continued monitoring of Wakix sales performance and further pipeline advancements.